Skip to main content
Clinical Trials/PACTR201510001305535
PACTR201510001305535
Completed
未知

A Randomized Controlled Clinical Study to Determine the Safety and Effectiveness of the REPAIR Bone Putty in Tibia Fractures

Carmell Therapeutics Corp.0 sites30 target enrollmentOctober 13, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Musculoskeletal Diseases
Sponsor
Carmell Therapeutics Corp.
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 13, 2015
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Carmell Therapeutics Corp.

Eligibility Criteria

Inclusion Criteria

  • Patients between the age of 18\-75 inclusive;
  • Patients with an acute open fracture of the tibial shaft secondary to trauma assessed by medical examination and radiograms indicated for open fracture reduction and mechanical fixation;
  • Definitive Wound Closure (DWC) within 14 days of initial injury;
  • In bilateral open tibia fractures, only one fracture meeting all inclusion/exclusion criteria will be treated ¿ should both fractures meet the criteria, the selected fracture will be randomly chosen;
  • ¿Subject is willing to be available for post operative follow\-up examinations;
  • Willingness and ability to understand, participate and comply with the study requirements;
  • Able to give consent personally and to sign the Consent Form;
  • Females of non\-childbearing potential or who have a negative pregnancy test with 72 hours.

Exclusion Criteria

  • Type IIIc open fracture according to the Gustilo\-Anderson classification;
  • Tibial defects requiring bone grafting (e.g., large segmental defects);
  • Duration from trauma to surgery longer than 14 days;
  • Concomitant acute bone injuries and/or major skin or other injuries that in the opinion of the investigator would interfere with the tibial shaft fracture healing process;
  • Active malignancy: a history of any invasive malignancy (except non\-melanoma skin cancer), unless the subject has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least five years;
  • Subject is participating in another investigational trial that has not completed the primary study endpoint phase;
  • Taking medication known to potentially interfere with bone/soft tissue healing (e.g., long term use of corticosteroids but not intended to exclude inhalation medication for asthma);
  • Active infection at the operative site or a systemic infection;
  • Any psychosocial disorders that could impact the follow up assessments or informed consent process.

Outcomes

Primary Outcomes

Not specified

Similar Trials